MCHX MARCHEX INC

Price Chart

Executive Summary

Marchex is seeking stockholder approval for a related-party acquisition of Archenia, Inc., from its Chairman (Russell Horowitz) and Vice Chairman (Michael Arends) for $10M in convertible notes (6% interest, $1.80/sh conversion, 12-24 month tranches) plus up to 4M earn-out shares subject to revenue/EBITDA and retention targets. Craig-Hallum issued a fairness opinion deeming total ~$16.5M consideration fair to Marchex stockholders. The special meeting is set for July 1, 2026, requiring both a majority vote and a majority-of-minority vote (excluding Horowitz and Arends). The deal is accounted for as a common-control transfer, not a business combination, so no goodwill or fair-value step-up is recognized.

Key Financial Metrics

Actionable Insight

Key Facts

• Marchex acquires 100% of Archenia from Chairman Russell Horowitz, Vice Chairman Michael Arends, and a third seller in a related-party transaction
• Consideration: $10M in convertible promissory notes (6% interest, $1.80/sh conversion price) plus up to 4M earn-out shares of Class B common stock
• Earn-out shares tied to Archenia achieving revenue or Adjusted EBITDA exceeding 100% of baseline levels AND completing software integration or retaining 75% of pre-closing customers
• Special Committee of independent directors negotiated deal; Craig-Hallum rendered fairness opinion valuing total consideration at ~$16.52M
• Transaction accounted for as common-control transfer (not business combination); no goodwill or intangible asset step-up
• Required approvals: majority of all outstanding voting power AND majority of minority (excluding Horowitz and Arends) - special meeting on July 1, 2026
• Archenia had 2025A revenue of $17.97M, income from operations of $392K, EBITDA of $457K; negative equity of -$1.79M
• Pro forma combined 2025 revenue: ~$63.3M (Marchex $45.4M + Archenia $17.97M); pro forma combined net loss: -$5.97M
• Archenia has $2.27M in shareholder loans and $1.48M accounts payable; cash of only $358K
• Material weakness in internal controls identified during Archenia's first audit, though unqualified opinion was issued

Financial Impact

Total deal value approximately $16.5M ($10M notes + up to ~$6.5M earn-out shares at $1.63/sh), representing ~22% of Marchex's $74M market cap

Risk Factors

• Related-party conflicts: Chairman and Vice Chairman are the sellers, creating inherent governance tension despite Special Committee process
• Customer concentration risk: Archenia's top four customers represent 63% of revenue; any defection post-closing directly hits earn-out metrics
• Integration execution risk: earn-out requires both financial performance AND software integration / 75% customer retention - a high bar for a small company
• Dilution risk: up to 4M shares at $1.63/sh (~10% of outstanding Class B) if earn-out fully achieved; notes also convertible at $1.80
• Leverage risk: $10M note payable over 24 months versus Marchex's $9.9M cash balance - cash flow could tighten
• Material internal control weakness at Archenia suggests potential for post-closing accounting surprises

Market Snapshot

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

US Market Status